LENZ Therapeutics is progressing rapidly with its LNZ100 for presbyopia, aiming for a 2025 U.S. launch in a market valued at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback